Cortical blindness following convulsions and fever in Nigerian children.
D000900:Anti-Bacterial Agents / Q000627:therapeutic use; D000927:Anticonvulsants / Q000627:therapeutic use; D001766:Blindness / Q000453:epidemiology / Q000209:etiology*; D001803:Blood Transfusion; D001996:Bronchopneumonia / Q000150:complications / Q000188:drug therapy; D002540:Cerebral Cortex / Q000473:pathology; D002560:Cerebrovascular Circulation; D002675:Child, Preschool; D002738:Chloroquine / Q000627:therapeutic use; D003231:Conjunctivitis / Q000150:complications / Q000188:drug therapy; D004660:Encephalitis / Q000150:complications / Q000188:drug therapy; D005260:Female; D005334:Fever / Q000150:complications*; D006801:Humans; D006810:Humeral Fractures; D007223:Infant; D008012:Lidocaine / Q000009:adverse effects; D008288:Malaria / Q000150:complications / Q000188:drug therapy; D008297:Male; D009549:Nigeria; D012640:Seizures / Q000150:complications*
D000900:Anti-Bacterial Agents; D000927:Anticonvulsants; D002738:Chloroquine; D008012:Lidocaine